Send us a text

Three possible scenarios for development of the NASH market.

Roger Green presents three possible directions for the NASH market over the next 5-10 years and asks our panelists, including our guest, renowned nurse and patient advocate Louise Campbell, to suggest critical market-driving factors.

Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/

Send us a text

Critical considerations for companies developing NASH drugs

Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh in on implications for clinical researchers, investors and forecasters in our third episode: C-SUITE COVID-19 CHALLENGES.

Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/

Send us a text

What investors want to know about NASH development during the pandemic.

Yasmeen Rahimi poses five questions NASH investors ask her about the impact of COVID-19 on NASH clinical and commercial development and our panelists provide answers in our second episode, FIVE $IMPLE PIECES: What investors want to know about NASH development during the pandemic.

Send us a text

Navigating NAFLD/NASH clinical trials through the pandemic

Dr. Stephen Harrison discusses several ways the pandemic is affecting planning and execution of clinical trials and our panelists discuss implications for investors, C-suite executives and forecasters in our first episode, COVID CHAOS: Navigating NAFLD/NASH clinical trials through the pandemic.

Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/